Disc Medicine Drug Meets Main and Secondary Goals in Late-Stage Trial
Disc Medicine said its experimental pill for a rare disease causing extreme pain from sunlight met all main and secondary goals in a late-stage trial. Shares surged 65% in premarket trading.
Disc Medicine (NASDAQ:IRON) said Monday that its experimental pill for a rare disease causing extreme pain from sunlight met all primary and secondary goals in a late-stage trial. The shares surged 65% in premarket trading.